marijuana stocks news

Cara Therapeutics to Webcast Presentation at Canaccord Genuity 36th Annual Growth Conference

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Canaccord Genuity 36thAnnual Growth Conference on Thursday, August 11, 2016, at 12:30 p.m. ET in Boston.

A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website atwww.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$MJNA Portfolio Company HempMeds At SOHO Expo

Medical Marijuana, Inc.’s HempMeds Shows Retail-Ready Cannabis Products at SOHO EXPO Industry…

Curaleaf Holdings, Inc. (CURLF) Unveils Strategic National Rebrand for Grassroots

Curaleaf Unveils Strategic National Rebrand for Grassroots Curaleaf Holdings, Inc. (CSE: CURA)…

$RSSFF Gets Sophisticated

Affinor Growers Announces New Sophisticated Vertical Design to Produce Marijuana Clones MONTREAL,…